We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
The Kindr Health Global Menopause & PMDD Economic Index quantifies what boards, ministries, and HR leaders have ignored for a generation: the compounding cost of untreated hormonal decline in women aged 35–60. Every number on this page is a deterministic projection from published prevalence and loss rates — refresh the tab and the counter keeps moving because time has passed.
Countries treating menopause as a cost center pay it three times: first in presenteeism, then in osteoporotic fractures, then in cardiovascular events. Ireland's free HRT scheme demonstrates the inverse — every euro spent on hormone therapy in perimenopause offsets an estimated three to seven euros in downstream orthopedic, cardiac, and psychiatric spend by age 70.
Menopause is not a health expense. It is one of the highest-return preventive investments in modern medicine — and one of the last major categories where that arbitrage is still open.
The women driving your P&L are not calling out sick. They are logging in, running the meeting, and quietly operating at 60–70% of their capacity through brain fog, night sweats, cyclical PMDD, and fractured sleep. The cost isn't in absenteeism — it's in silent productivity loss that never shows up on an HR dashboard.
The Kindr Index estimates presenteeism accounts for roughly 4.2× the direct medical cost of untreated menopause per employee, per year.
The strongest clinical pull is for non-hormonal options. Kindr Health offers clinician-directed PMDD screening, SSRI-based treatment pathways, and digital symptom tracking — all from home.
Employers are losing top female talent to presenteeism and turnover. Calculate the ROI of implementing the Kindr Health Menopause Protocol across your workforce.
~47M women/year globally (WHO demographic projections; Harlow et al. 2012 STRAW+10) → 1.49/sec deterministic increment.
Mayo Clinic Proceedings 2023 US $1.8B/yr direct loss scaled to global working-age female cohort × PwC 2024 menopause market analysis → ~$150B/yr → $4,754/sec.
1.6% of ~1.9B menstruating women worldwide (Halbreich et al., Psychoneuroendocrinology; ACOG PMDD guidance) → baseline 30.14M, slow drift for demographic change.
All counters are deterministic: they are computed from a fixed 2025-01-01 UTC epoch and the published rates above, so every visitor sees the same value at the same moment. Numbers are population-level projections, not patient-level data, and are not a substitute for clinical statistics from WHO, CDC, or national health authorities.